| Age (years, median [interquartile range]) |
68 (55–75) |
| Male, n (%) |
673 (76) |
| Etiologies of liver disease |
|
| HBV, n (%) |
311 (35) |
| HCV, n (%) |
241 (27) |
| HBV+HCV, n (%) |
35 (4) |
| Alcohol, n (%) |
162 (19) |
| Diabetes mellitus, n (%) |
226 (26) |
| Performance status (0/1/2/3/4), n (%) |
521/207/106/39/8 (59/24/12/4/1) |
| Ascites, n (%) |
166 (18) |
| Laboratory values |
|
| α-fetoprotein (ng/mL), mean ± SD |
13515.0 ± 98741.32 |
| Alanine aminotransferase (IU/L), mean± SD |
67.2±70.1 |
| Aspartate aminotransferase (IU/L), mean± SD |
94.2± 184.1 |
| Alkaline phosphatase (IU/L), mean± SD |
138.62±103.77 |
| Albumin (g/L), mean ± SD |
36± 6 |
| Total bilirubin (μmol/L), mean ± SD |
18.8 ± 16.6 |
| Creatinine (mg/dl), mean ± SD |
1.151±0.956 |
| Platelets (1,000/μL), mean ± SD |
160± 95 |
| INR of prothrombin time (mean ± SD) |
1.1 ± 0.2 |
| Non-invasive liver reserve markers |
|
| ALBI grade (1/2/3), n (%) |
297/540/44 (34/61/5) |
| APRI grade (1/2/3), n (%) |
195/368/318 (22/42/36) |
| CTP classification (A/B/C), n (%) |
698/263/20 (79/19/2) |
| CDS grade (1/2/3), n (%) |
209/500/172 (24/56/20) |
| FIB-4 grade (1/2/3), n (%) |
401/234/246 (45/27/28) |
| GUCI grade (1/2/3), n (%) |
154/362/365 (18/41/41) |
| Lok index grade (1/2/3), n (%) |
365/298/218 (41/34/25) |
| MELD score (<10/10-14/>14), n (%) |
613/202/66 (70/23/7) |
| Tumor nodules (1/2/≥3), n (%) |
442/177/262 (50/20/30) |
| Maximal tumor diameter (≤2/ 2-5/ >5cm), n (%) |
121/329/431 (14/37/49) |
| Vascular invasion, n (%) |
157 (18%) |
